Investing.com - Viridian Therapeutics (NASDAQ: VRDN) reported first quarter EPS of $-1.13, $0.41 worse than the analyst estimate of $-0.72. Revenue for the quarter came in at $105K versus the consensus estimate of $457.6K.
Viridian Therapeutics's stock price closed at $32.92. It is up 21.70% in the last 3 months and up 67.62% in the last 12 months.
Viridian Therapeutics saw 5 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Viridian Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Viridian Therapeutics's Financial Health score is "weak performance".
Check out Viridian Therapeutics's recent earnings performance, and Viridian Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar